Core Insights - Decoy Therapeutics, Inc. announced participation in a Virtual Investor segment discussing its Global Access Commitment Agreement (GACA) with the Gates Foundation, focusing on developing a scalable manufacturing platform for peptide-conjugate therapeutics [1][2] Group 1: Company Overview - Decoy Therapeutics is a preclinical-stage biotechnology company utilizing machine learning and AI tools alongside high-speed synthesis techniques to design and manufacture peptide conjugate drug candidates targeting unmet medical needs, particularly in respiratory viruses and gastrointestinal cancers [5] - The company has secured financing from institutional investors and non-dilutive capital sources, including the Massachusetts Life Sciences Seed Fund and the Google AI startup program [5] Group 2: Manufacturing Platform - The company is developing a flexible, globally accessible manufacturing platform for peptide-conjugate antivirals, aimed at rapid and cost-efficient production, particularly for low- and middle-income countries [2] - The platform will be validated using Decoy's intranasal pan-coronavirus fusion inhibitor, which is funded under the Gates Foundation grant [3] Group 3: Strategic Approach - Decoy's "design-for-manufacturing" approach facilitates the transition of therapeutics from laboratory development to commercial-scale production, enabling a distributed global manufacturing network to respond to emerging viral threats [3]